Analisis Cost of Illness Terapi Insulin dan Kombinasi Insulin-Metformin pada Pasien Diabetes Melitus Tipe 2 di Salah Satu Rumah Sakit di Bandung
Abstract
Diabetes melitus (DM) tipe 2 merupakan suatu penyakit progresif yang berdampak pada biaya yang dikeluarkan pasien selama mengidap penyakit ini. Penelitian ini dilakukan dari bulan Mei hingga Juni di salah satu rumah sakit di Bandung. Penelitian ini bertujuan untuk memperoleh perhitungan biaya kesakitan penggunaan insulin monoterapi dan kombinasi insulin-metformin pada pasien DM tipe 2 dengan menggunakan analisis Cost of Illness (COI). Penelitian ini menggunakan metode potong lintang dengan pengambilan data secara retrospektif pada objek penelitian pasien rawat jalan dengan lama terapi selama 6 bulan pada tahun 2013. Komponen biaya yang diukur adalah biaya medik langsung (biaya kunjungan ke dokter, biaya obat, biaya komplikasi dan biaya pemeriksaan laboratorium) dan human capital (HC) seperti biaya tidak langsung non-medis (kehilangan pendapatan per hari). Hasil penelitian menunjukkan nilai COI selama 6 bulan terapi dengan insulin dan kombinasi insulin-metformin secara berurutan Rp661.063,59 dan Rp443.165,28. Penelitian ini menunjukkan bahwa penggunaan terapi kombinasi insulin-metformin memiliki biaya kesakitan yang lebih rendah dibandingkan dengan terapi insulin tunggal dan secara statistik (student t-test) menunjukkan perbedaan yang signifikan p=0,004 (p<0,05).
Kata kunci: COI, diabetes melitus tipe 2, insulin, kombinasi insulin-metformin
Cost of Illness Analysis of Insulin and Insulin-Metformin Combination Usage towards Diabetes Mellitus Type 2 Patients at Hospital in Bandung
Diabetes mellitus (DM) type 2 is a progressive disease that impact on the patients incurred costs during the illness. This study was conducted on May to June at one of hospital in Bandung. This study aimed to obtain cost of illness calculation of insulin monotherapy and insulin-metformin combination in patients with type 2 diabetes using Cost of Illness analysis (COI). This study used cross-sectional method with retrospective data collection on outpatients with 6 months therapy period in 2013. The cost of the measured components are direct medical costs (the cost of doctor visits, medicine costs, costs of complications and the cost of laboratories test) and human capital (HC) such as indirect non-medical costs (lost revenue per day). The results show the value of COI in the six months treatment of insulin and insulin-metformin combination sequentially 661,063.59 IDR and 443,165.28 IDR. This study shows that the use of combination therapy of insulin-metformin has lower cost of illness compared with insulin monotherapy and statistically (student t-test) showed significant differences p=0.004 (p<0.05).
Keywords: COI, diabetes mellitus type 2, insulin, insulin-metformin combination
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Perkumpulan Endokrinologi Indonesia (PERKENI). Practical guide: Insulin therapy on type 2 diabetes mellitus. Jakarta: PB Perkeni; 2006.
Primadiamanti A, Andayani TM. Cost-effectiveness analysis of insulin and insulin-metformin combination use in type 2 diabetes mellitus patients. Jurnal Farmasi Indonesia. 2009;4(3):146–55.
González JC, Walker JH, Einarson TR. Cost-of illness study of type 2 diabetes mellitus in Colombia. Rev Panam Salud Publica. 2009;26(1):55–63.
Sudoyo AW, Setiati S, Alwi I, Simadibrata M, Setiyohadi B, Syam AF. Internal medicine textbook, 5th Edition, Volume 2. Jakarta: Interna Publishing; 2009.
Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361 :1736–47. doi: 10.1056/NEJMoa0905479
Helena WR, Paul SJ, Zachary TB, Daniel Einhorn, Alan JG, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. American Association of Clinical Endocrinology. 2009;15(6):540–59. doi: 10.4158/EP.15.6.540
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203. doi: 10.2337/dc08-9025.
Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, et al. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ. 2009;339:b4324. doi: 10.1136/bmj.b4324
Hamaty M. Insulin treatment for type 2 diabetes: When to start, which to use. Cleve Clin J Med. 2011;78(5):332–42. doi: 10.3949/ccjm.78a.10051.
Sinuraya RK, Destiani DP, Abdulah R. Cost of illness and cost containment analysis penggunaan antibiotic empiric kombinasi pada pasien sepsis di Bandung. Indones J Clin Pharm. 2012;1(4):127–35.
Galani V, Patel HM. Comparison of metformin and insulin monotherapy with combined metformin and insulin therapy in patient of type 2 diabetes with HbA1c >7%. Int Journal Pharmaceutical Biol Arch. 2011;2:563–8.
DOI: https://doi.org/10.15416/ijcp.2018.7.1.10
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
